BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ. 2014;348:g3308. [PMID: 25002352 DOI: 10.1136/bmj.g3308] [Cited by in Crossref: 142] [Cited by in F6Publishing: 135] [Article Influence: 17.8] [Reference Citation Analysis]
Number Citing Articles
1 Serumondo J, Shilton S, Nshimiyimana L, Karame P, Dushimiyimana D, Fajardo E, Remera E, Rwibasira GN, Martínez-Pérez GZ. Values and preferences for hepatitis C self-testing among the general population and healthcare workers in Rwanda. BMC Infect Dis 2021;21:1064. [PMID: 34649503 DOI: 10.1186/s12879-021-06773-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bose M, Kamra M, Mullick R, Bhattacharya S, Das S, Karande AA. A plant-derived dehydrorotenoid: a new inhibitor of hepatitis C virus entry. FEBS Lett 2017;591:1305-17. [DOI: 10.1002/1873-3468.12629] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
3 Magri A, Ozerov AA, Tunitskaya VL, Valuev-Elliston VT, Wahid A, Pirisi M, Simmonds P, Ivanov AV, Novikov MS, Patel AH. Exploration of acetanilide derivatives of 1-(ω-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replication. Sci Rep 2016;6:29487. [PMID: 27406141 DOI: 10.1038/srep29487] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
4 Chu CE, Wu F, He X, Zhou K, Cheng Y, Cai W, Geng E, Volberding P, Tucker JD. Hepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion. Open Forum Infect Dis 2016;3:ofw065. [PMID: 27419150 DOI: 10.1093/ofid/ofw065] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
5 FakhriRavari A, Malakouti M, Brady R. Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection. J Clin Transl Hepatol 2016;4:97-112. [PMID: 27350940 DOI: 10.14218/JCTH.2016.00007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
6 Wang YK, Lee WP, Wang YW, Huang YH, Hou MC, Chang YL, Lan KH. Precipitating factors causing hyperbilirubinemia during chronic hepatitis C treatment with paritaprevir/ritonavir/ombitasvir and dasabuvir. J Chin Med Assoc 2020;83:1071-8. [PMID: 33273269 DOI: 10.1097/JCMA.0000000000000429] [Reference Citation Analysis]
7 Chung CY, Liu CH, Wang GH, Jassey A, Li CL, Chen L, Yen MH, Lin CC, Lin LT. (4R,6S)-2-Dihydromenisdaurilide is a Butenolide that Efficiently Inhibits Hepatitis C Virus Entry. Sci Rep 2016;6:29969. [PMID: 27426693 DOI: 10.1038/srep29969] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
8 Kamarulzaman A, Altice FL. Challenges in managing HIV in people who use drugs. Curr Opin Infect Dis 2015;28:10-6. [PMID: 25490106 DOI: 10.1097/QCO.0000000000000125] [Cited by in Crossref: 58] [Cited by in F6Publishing: 42] [Article Influence: 8.3] [Reference Citation Analysis]
9 Saab S, Jimenez M, Fong T, Wu C, Bau S, Jamal Z, Grotts J, Elashoff D. Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States. J Clin Transl Hepatol 2016;4:76-82. [PMID: 27350937 DOI: 10.14218/JCTH.2016.00011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
10 Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52:1898-1907. [PMID: 33268834 DOI: 10.1038/s12276-020-00527-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
11 Gokhale NS, Vazquez C, Horner SM. Hepatitis C Virus. Strategies to Evade Antiviral Responses. Future Virol 2014;9:1061-75. [PMID: 25983854 DOI: 10.2217/fvl.14.89] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
12 Stahmeyer JT, Rossol S, Krauth C. Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals. J Comp Eff Res 2015;4:267-77. [PMID: 25960028 DOI: 10.2217/cer.15.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
13 Li JR, Li WJ, Cheng JJ, Huang MH, Wu ZY, Jiang CC, Li H, Chen JH, Lv XQ, Dong B, Jiang JD, Peng ZG. A Simple but Accurate Method for Evaluating Drug-Resistance in Infectious HCVcc System. Biomed Res Int 2017;2017:1236801. [PMID: 28904942 DOI: 10.1155/2017/1236801] [Reference Citation Analysis]
14 Saab S, Greenberg A, Li E, Bau SN, Durazo F, El-Kabany M, Han S, Busuttil RW. Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients. Liver Int. 2015;35:2442-2447. [PMID: 25913321 DOI: 10.1111/liv.12856] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
15 Fevery B, Susser S, Lenz O, Cloherty G, Perner D, Gilles L, De Locht P, Picchio G, De Meyer S, Sarrazin C. Comparison of three quantitative HCV RNA assays in samples from HCV genotype 1- or 4-infected patients treated with the NS3/4A protease inhibitor simeprevir. J Clin Virol 2015;72:133-40. [PMID: 26513763 DOI: 10.1016/j.jcv.2015.09.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
16 Lafeuillade A, Wainberg M, Gougeon ML, Loes SK, Halfon P, Tissot-Dupont H. Highlights from the 2014 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the end of the HIV pandemic. AIDS Res Ther 2014;11:28. [PMID: 25165483 DOI: 10.1186/1742-6405-11-28] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Goel A, Bhargava R, Rai P, Aggarwal R. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience. Indian J Gastroenterol 2017;36:227-34. [PMID: 28656492 DOI: 10.1007/s12664-017-0763-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
18 Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kính N, Calistru P, Heo J. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Aliment Pharmacol Ther. 2015;42:829-844. [PMID: 26238707 DOI: 10.1111/apt.13342] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
19 Kong L, Kadam RU, Giang E, Ruwona TB, Nieusma T, Culhane JC, Stanfield RL, Dawson PE, Wilson IA, Law M. Structure of Hepatitis C Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex with Antibody IGH526. J Mol Biol 2015;427:2617-28. [PMID: 26135247 DOI: 10.1016/j.jmb.2015.06.012] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
20 Altınbas S, Holmes JA, Altınbas A. Hepatitis C Virus Infection in Pregnancy: An Update. Gastroenterol Nurs 2020;43:12-21. [PMID: 31990870 DOI: 10.1097/SGA.0000000000000404] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
21 George N, Liapakis A, Korenblat KM, Li T, Roth D, Yee J, Fowler KJ, Howard L, Liu J, Politi MC. A Patient Decision Support Tool for Hepatitis C Virus and CKD Treatment. Kidney Med 2019;1:200-6. [PMID: 32734200 DOI: 10.1016/j.xkme.2019.06.003] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Leblebicioglu H, Arends JE, Ozaras R, Corti G, Santos L, Boesecke C, Ustianowski A, Duberg AS, Ruta S, Salkic NN, Husa P, Lazarevic I, Pineda JA, Pshenichnaya NY, Tsertswadze T, Matičič M, Puca E, Abuova G, Gervain J, Bayramli R, Ahmeti S, Koulentaki M, Kilani B, Vince A, Negro F, Sunbul M, Salmon D; ESGHV (part of ESCMID). Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries. Antiviral Res 2018;150:9-14. [PMID: 29217468 DOI: 10.1016/j.antiviral.2017.12.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
23 Shimura S, Watashi K, Fukano K, Peel M, Sluder A, Kawai F, Iwamoto M, Tsukuda S, Takeuchi JS, Miyake T, Sugiyama M, Ogasawara Y, Park SY, Tanaka Y, Kusuhara H, Mizokami M, Sureau C, Wakita T. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity. J Hepatol. 2017;66:685-692. [PMID: 27890789 DOI: 10.1016/j.jhep.2016.11.009] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 10.2] [Reference Citation Analysis]
24 Vitor S, Marinho RT, Gíria J, Velosa J. An observational study of the direct costs related to hospital admissions, mortality and premature death associated with liver disease in Portugal. BMC Res Notes 2016;9:62. [PMID: 26843372 DOI: 10.1186/s13104-016-1879-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
25 van de Vooren K, Curto A, Garattini L. Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness? Eur J Health Econ 2015;16:341-5. [DOI: 10.1007/s10198-014-0653-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
26 Goossens N, Hoshida Y. Personalized management of hepatocellular carcinoma based on molecular information: future prospects. Clin Liver Dis (Hoboken) 2015;5:132-5. [PMID: 26213619 DOI: 10.1002/cld.483] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
27 Pastuch-Gawolek G, Chaubey B, Szewczyk B, Krol E. Novel thioglycosyl analogs of glycosyltransferase substrates as antiviral compounds against classical swine fever virus and hepatitis C virus. Eur J Med Chem 2017;137:247-62. [PMID: 28601004 DOI: 10.1016/j.ejmech.2017.05.051] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
28 Climent J, Morandeira F, Castellote J, Xiol J, Niubó J, Calatayud L, Mestre M, Bas J. Clinical correlates of the "rods and rings" antinuclear antibody pattern. Autoimmunity 2016;49:102-8. [PMID: 26699543 DOI: 10.3109/08916934.2015.1118762] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
29 Simpson CL, McCausland D, Chu EY. Photo-distributed lichenoid eruption secondary to direct anti-viral therapy for hepatitis C. J Cutan Pathol 2015;42:769-73. [PMID: 25974215 DOI: 10.1111/cup.12532] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
30 Cusato J, Allegra S, De Nicolò A, Boglione L, Fatiguso G, Cariti G, Ciancio A, Smedile A, Strona S, Troshina G, Rizzetto M, Di Perri G, D'Avolio A. ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy. Biomed Pharmacother 2015;69:63-9. [PMID: 25661339 DOI: 10.1016/j.biopha.2014.11.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
31 Pecoraro V, Banzi R, Cariani E, Chester J, Villa E, D'Amico R, Bertele' V, Trenti T. New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials. J Clin Exp Hepatol 2019;9:522-38. [PMID: 31516269 DOI: 10.1016/j.jceh.2018.07.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
32 Goossens N, Sun X, Hoshida Y. Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol 2015;2:371-9. [PMID: 26617981 DOI: 10.2217/hep.15.26] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 9.0] [Reference Citation Analysis]
33 White KM, De Jesus P, Chen Z, Abreu P Jr, Barile E, Mak PA, Anderson P, Nguyen QT, Inoue A, Stertz S, Koenig R, Pellecchia M, Palese P, Kuhen K, García-Sastre A, Chanda SK, Shaw ML. A Potent Anti-influenza Compound Blocks Fusion through Stabilization of the Prefusion Conformation of the Hemagglutinin Protein. ACS Infect Dis 2015;1:98-109. [PMID: 25984567 DOI: 10.1021/id500022h] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
34 Fernandes TA, Manvar D, Domingos JLO, Basu A, Nichols DB, Kaushik-Basu N, Costa PRR. 5-Carba-pterocarpens: A new scaffold with anti-HCV activity. Eur J Med Chem 2016;112:33-8. [PMID: 26874742 DOI: 10.1016/j.ejmech.2016.02.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
35 Zhang Y, Chen LM, He M. Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution. Virol J. 2017;14:41. [PMID: 28231805 DOI: 10.1186/s12985-017-0710-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
36 Karsdal MA, Manon-Jensen T, Genovese F, Kristensen JH, Nielsen MJ, Sand JM, Hansen NU, Bay-Jensen AC, Bager CL, Krag A, Blanchard A, Krarup H, Leeming DJ, Schuppan D. Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2015;308:G807-30. [PMID: 25767261 DOI: 10.1152/ajpgi.00447.2014] [Cited by in Crossref: 138] [Cited by in F6Publishing: 132] [Article Influence: 19.7] [Reference Citation Analysis]
37 You Y, Kim HS, Park JW, Keum G, Jang SK, Kim BM. Sulfur( vi ) fluoride exchange as a key reaction for synthesizing biaryl sulfate core derivatives as potent hepatitis C virus NS5A inhibitors and their structure–activity relationship studies. RSC Adv 2018;8:31803-21. [DOI: 10.1039/c8ra05471a] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
38 Kong L, Lee DE, Kadam RU, Liu T, Giang E, Nieusma T, Garces F, Tzarum N, Woods VL Jr, Ward AB, Li S, Wilson IA, Law M. Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen. Proc Natl Acad Sci U S A 2016;113:12768-73. [PMID: 27791120 DOI: 10.1073/pnas.1609780113] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 8.7] [Reference Citation Analysis]
39 Andersohn F, Claes AK, Kulp W, Mahlich J, Rockstroh JK. Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison. BMC Infect Dis 2016;16:10. [PMID: 26753774 DOI: 10.1186/s12879-015-1311-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
40 Salazar-Vizcaya L, Kouyos RD, Zahnd C, Wandeler G, Battegay M, Darling KE, Bernasconi E, Calmy A, Vernazza P, Furrer H, Egger M, Keiser O, Rauch A; Swiss HIV Cohort Study. Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions. Hepatology 2016;64:1856-69. [PMID: 27531615 DOI: 10.1002/hep.28769] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 10.0] [Reference Citation Analysis]
41 Kim JS, Knickelbein JE, Nussenblatt RB, Sen HN. Clinical trials in noninfectious uveitis. Int Ophthalmol Clin 2015;55:79-110. [PMID: 26035763 DOI: 10.1097/IIO.0000000000000070] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
42 Villar LM, Cruz HM, Barbosa JR, Bezerra CS, Portilho MM, Scalioni LP. Update on hepatitis B and C virus diagnosis. World J Virology 2015; 4(4): 323-342 [PMID: 26568915 DOI: 10.5501/wjv.v4.i4.323] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
43 Trickey A, May MT, Davies C, Qureshi H, Hamid S, Mahmood H, Saeed Q, Hickman M, Glass N, Averhoff F, Vickerman P. Importance and Contribution of Community, Social, and Healthcare Risk Factors for Hepatitis C Infection in Pakistan. Am J Trop Med Hyg 2017;97:1920-8. [PMID: 29141707 DOI: 10.4269/ajtmh.17-0019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
44 Yuen MF, Liu SH, Seto WK, Mak LY, Corman SL, Hsu DC, Lee MYK, Khan TK, Puenpatom A. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong. Dig Dis Sci 2021;66:1315-26. [PMID: 32385703 DOI: 10.1007/s10620-020-06281-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
45 Boesecke C, Page E. Direct-acting antiviral-based therapy for acute hepatitis C coinfection. Curr Opin HIV AIDS 2015;10:330-6. [PMID: 26248120 DOI: 10.1097/COH.0000000000000181] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Lu Y, Hardes K, Dahms SO, Böttcher-Friebertshäuser E, Steinmetzer T, Than ME, Klenk HD, Garten W. Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells. Antiviral Res 2015;120:89-100. [PMID: 26022200 DOI: 10.1016/j.antiviral.2015.05.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
47 Hung TC, Jassey A, Liu CH, Lin CJ, Lin CC, Wong SH, Wang JY, Yen MH, Lin LT. Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein. Phytomedicine 2019;53:62-9. [PMID: 30668413 DOI: 10.1016/j.phymed.2018.09.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
48 Lapi F, Capogrosso Sansone A, Mantarro S, Simonetti M, Tuccori M, Blandizzi C, Rossi A, Corti G, Bartoloni A, Bellia A, Baiocchi L, Cricelli I, Cricelli C. Hepatitis C virus infection: opportunities for an earlier detection in primary care. Eur J Gastroenterol Hepatol 2017;29:271-6. [PMID: 27849644 DOI: 10.1097/MEG.0000000000000785] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
49 Olson JC. Acute-on-chronic and Decompensated Chronic Liver Failure: Definitions, Epidemiology, and Prognostication. Crit Care Clin 2016;32:301-9. [PMID: 27339672 DOI: 10.1016/j.ccc.2016.02.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
50 Greenaway C, Azoulay L, Allard R, Cox J, Tran VA, Abou Chakra CN, Steele R, Klein M. A population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, Canada. BMC Infect Dis 2017;17:140. [PMID: 28193199 DOI: 10.1186/s12879-017-2242-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
51 Altinbas A. A quick overview to the early phase clinical trials of Simtuzumab®: Are we loosing the most promising anti-fibrotic product? Medical Hypotheses 2017;108:159-60. [DOI: 10.1016/j.mehy.2017.09.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
52 Osna NA, Carter WG, Ganesan M, Kirpich IA, McClain CJ, Petersen DR, Shearn CT, Tomasi ML, Kharbanda KK. Aberrant post-translational protein modifications in the pathogenesis of alcohol-induced liver injury. World J Gastroenterol 2016; 22(27): 6192-6200 [PMID: 27468209 DOI: 10.3748/wjg.v22.i27.6192] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
53 Mihm S. Activation of Type I and Type III Interferons in Chronic Hepatitis C. J Innate Immun. 2015;7:251-259. [PMID: 25766746 DOI: 10.1159/000369973] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
54 Cao Y, Zhang Y, Bao Y, Zhang R, Zhang X, Xia W, Wu H, Xu X. Naturally occurring hepatitis C virus protease inhibitors resistance-associated mutations among chronic hepatitis C genotype 1b patients with or without HIV co-infection. Hepatol Res 2016;46:552-8. [PMID: 26355704 DOI: 10.1111/hepr.12590] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
55 Wright AJ, Gill JS. Kidney Transplantation in HIV-Infected Recipients: Encouraging Outcomes, but Registry Data Are No Longer Enough. J Am Soc Nephrol 2015;26:2070-1. [PMID: 25791726 DOI: 10.1681/ASN.2015010059] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
56 Tang W, Chen W, Amini A, Boeras D, Falconer J, Kelly H, Peeling R, Varsaneux O, Tucker JD, Easterbrook P. Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-analysis and review of the literature. BMC Infect Dis 2017;17:695. [PMID: 29143615 DOI: 10.1186/s12879-017-2773-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 10.2] [Reference Citation Analysis]
57 Johnston SA, Domenyuk V, Gupta N, Batista MT, Lainson JC, Zhao ZG, Lusk JF, Loskutov A, Cichacz Z, Stafford P, Legutki JB, Diehnelt CW. A Simple Platform for the Rapid Development of Antimicrobials. Sci Rep 2017;7:17610. [PMID: 29242618 DOI: 10.1038/s41598-017-17941-7] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
58 Frey A, Ecker EM, Piras-Straub K, Walker A, Hofmann TG, Timm J, Singer BB, Gerken G, Herzer K. Effects of the Mammalian Target of Rapamycin Inhibitor Everolimus on Hepatitis C Virus Replication In Vitro and In Vivo. Transplant Proc 2017;49:1947-55. [PMID: 28923653 DOI: 10.1016/j.transproceed.2017.04.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
59 Suthar AB, Harries AD. A public health approach to hepatitis C control in low- and middle-income countries. PLoS Med. 2015;12:e1001795. [PMID: 25757228 DOI: 10.1371/journal.pmed.1001795] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
60 Gomes RG, Isken O, Tautz N, McLauchlan J, McCormick CJ. Polyprotein-Driven Formation of Two Interdependent Sets of Complexes Supporting Hepatitis C Virus Genome Replication. J Virol 2015;90:2868-83. [PMID: 26719260 DOI: 10.1128/JVI.01931-15] [Reference Citation Analysis]
61 Gummow J, Li Y, Yu W, Garrod T, Wijesundara D, Brennan AJ, Mullick R, Voskoboinik I, Grubor-Bauk B, Gowans EJ. A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice. J Virol 2015;89:7991-8002. [PMID: 26018154 DOI: 10.1128/JVI.00803-15] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
62 Parola M. Age-dependent changes in extracellular matrix turnover: An under evaluated issue in the approach to chronic liver diseases. J Hepatol 2016;64:13-5. [PMID: 26432685 DOI: 10.1016/j.jhep.2015.09.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
63 Boesecke C, Rockstroh JK. How will we manage acute HCV in men having sex with men in the era of all oral therapy? J Viral Hepat 2015;22:2-7. [PMID: 25333810 DOI: 10.1111/jvh.12348] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
64 Greenaway C, Thu Ma A, Kloda LA, Klein M, Cnossen S, Schwarzer G, Shrier I. The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis. PLoS One. 2015;10:e0141715. [PMID: 26558905 DOI: 10.1371/journal.pone.0141715] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
65 Braun DL, Rauch A, Aouri M, Durisch N, Eberhard N, Anagnostopoulos A, Ledergerber B, Müllhaupt B, Metzner KJ, Decosterd L, Böni J, Weber R, Fehr J; Swiss HIV Cohort Study. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. PLoS One 2015;10:e0133028. [PMID: 26176696 DOI: 10.1371/journal.pone.0133028] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
66 Zhou K, Liang Z, Wang C, Hu F, Ning C, Lan Y, Tang X, Tucker JD, Cai W. Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China. PLoS One 2016;11:e0157438. [PMID: 27341031 DOI: 10.1371/journal.pone.0157438] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
67 Grüner N, Viazov S, Korn K, Knöll A, Trippler M, Schlaak JF, Gerken G, Roggendorf M, Ross RS. Performance characteristics of the VERSANT hepatitis C virus RNA 1.0 (kPCR) assay. Int J Med Microbiol 2015;305:627-35. [PMID: 26384868 DOI: 10.1016/j.ijmm.2015.08.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
68 Andreev IA, Manvar D, Barreca ML, Belov DS, Basu A, Sweeney NL, Ratmanova NK, Lukyanenko ER, Manfroni G, Cecchetti V, Frick DN, Altieri A, Kaushik-Basu N, Kurkin AV. Discovery of the 2-phenyl-4,5,6,7-Tetrahydro-1H-indole as a novel anti-hepatitis C virus targeting scaffold. Eur J Med Chem 2015;96:250-8. [PMID: 25890075 DOI: 10.1016/j.ejmech.2015.04.022] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
69 Lanave G, Cavalli A, Martella V, Fontana T, Losappio R, Tempesta M, Decaro N, Buonavoglia D, Camero M. Ribavirin and boceprevir are able to reduce Canine distemper virus growth in vitro. J Virol Methods 2017;248:207-11. [PMID: 28760649 DOI: 10.1016/j.jviromet.2017.07.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
70 Rodriguez-Manzano J, Karymov MA, Begolo S, Selck DA, Zhukov DV, Jue E, Ismagilov RF. Reading Out Single-Molecule Digital RNA and DNA Isothermal Amplification in Nanoliter Volumes with Unmodified Camera Phones. ACS Nano 2016;10:3102-13. [PMID: 26900709 DOI: 10.1021/acsnano.5b07338] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 12.3] [Reference Citation Analysis]
71 Shah R, Reyes-Gordillo K, Cheng Y, Varatharajalu R, Ibrahim J, Lakshman MR. Thymosin β4 Prevents Oxidative Stress, Inflammation, and Fibrosis in Ethanol- and LPS-Induced Liver Injury in Mice. Oxid Med Cell Longev 2018;2018:9630175. [PMID: 30116499 DOI: 10.1155/2018/9630175] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
72 Pozza R, Hill C, Hefner AM, Vawter B, Hassanein T. Hepatitis C infection: Updates on treatment guidelines. Nurse Pract 2017;42:14-23. [PMID: 28379888 DOI: 10.1097/01.NPR.0000515423.38284.28] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Mayes BA, Wang J, Arumugasamy J, Arunachalam K, Baloglu E, Bauer D, Becker A, Chaudhuri N, Glynn R, Latham GM, Li J, Lim J, Liu J, Mathieu S, Mcgarry FP, Rosinovsky E, Soret AF, Stewart A, Moussa A. Scalable Synthesis of a Nucleoside Phosphoramidate Prodrug Inhibitor of HCV NS5B RdRp: Challenges in the Production of a Diastereomeric Mixture. Org Process Res Dev 2015;19:520-30. [DOI: 10.1021/op5003837] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
74 Borba HH, Wiens A, Steimbach LM, Tonin FS, Pedroso M, Ivantes CA, Fernandez-Llimos F, Pontarolo R. Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study. Ther Clin Risk Manag 2017;13:59-64. [PMID: 28138248 DOI: 10.2147/TCRM.S124663] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
75 Zhou N, Hernandez D, Ueland J, Yang X, Yu F, Sims K, Yin PD, McPhee F. NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection. J Infect Dis 2016;213:206-15. [PMID: 26170396 DOI: 10.1093/infdis/jiv379] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
76 Attar BM, Van Thiel DH. Hepatitis C virus: A time for decisions. Who should be treated and when? World J Gastrointest Pharmacol Ther 2016; 7(1): 33-40 [PMID: 26855810 DOI: 10.4292/wjgpt.v7.i1.33] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
77 Athanasakis K, Ferrante SA, Kyriopoulos II, Petrakis I, Hill M, Retsa MP, Kyriopoulos J. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis. Clin Ther 2015;37:1529-40. [PMID: 26031617 DOI: 10.1016/j.clinthera.2015.05.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
78 Nguyen LT, Nguyen VTT, Le Ai KA, Truong MB, Tran TTM, Jamil MS, Johnson C, Reipold EI, Easterbrook P, Park K. Acceptability and Usability of HCV Self-Testing in High Risk Populations in Vietnam. Diagnostics (Basel) 2021;11:377. [PMID: 33672241 DOI: 10.3390/diagnostics11020377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
79 García-niño WR, Zazueta C. Ellagic acid: Pharmacological activities and molecular mechanisms involved in liver protection. Pharmacological Research 2015;97:84-103. [DOI: 10.1016/j.phrs.2015.04.008] [Cited by in Crossref: 123] [Cited by in F6Publishing: 95] [Article Influence: 17.6] [Reference Citation Analysis]
80 Dembek C, Protzer U, Roggendorf M. Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination. Curr Opin Virol 2018;30:58-67. [PMID: 29751272 DOI: 10.1016/j.coviro.2018.04.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 9.3] [Reference Citation Analysis]
81 Daniel R, Lowry S, Pall H. State of the art vaccination strategies as primary prevention to reduce incidence of gastrointestinal cancers. J Gastrointest Oncol 2021;12:S316-23. [PMID: 34422396 DOI: 10.21037/jgo.2020.01.02] [Reference Citation Analysis]
82 Chan EY, Bhattacharya R, Eswaran S, Hertl M, Shah N, Fayek S, Cohen EB, Hollinger EF, Olaitan O, Jensik SC, Perkins JD. Outcomes after combined liver-kidney transplant vs. kidney transplant followed by liver transplant. Clin Transplant 2015;29:60-6. [DOI: 10.1111/ctr.12484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
83 Yang J, Zhang Y, Luo L, Meng R, Yu C. Global Mortality Burden of Cirrhosis and Liver Cancer Attributable to Injection Drug Use, 1990-2016: An Age-Period-Cohort and Spatial Autocorrelation Analysis. Int J Environ Res Public Health 2018;15:E170. [PMID: 29361804 DOI: 10.3390/ijerph15010170] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
84 Fichter M, Piradashvili K, Pietrzak-Nguyen A, Pretsch L, Kuhn G, Strand S, Knuf M, Zepp F, Wurm FR, Mailänder V, Landfester K, Gehring S. Polymeric hepatitis C virus non-structural protein 5A nanocapsules induce intrahepatic antigen-specific immune responses. Biomaterials 2016;108:1-12. [PMID: 27614817 DOI: 10.1016/j.biomaterials.2016.08.046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
85 Marascio N, Pavia G, Strazzulla A, Dierckx T, Cuypers L, Vrancken B, Barreca GS, Mirante T, Malanga D, Oliveira DM, Vandamme AM, Torti C, Liberto MC, Focà A; The SINERGIE-UMG Study Group. Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naïve Patients. Int J Mol Sci 2016;17:E1416. [PMID: 27618896 DOI: 10.3390/ijms17091416] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
86 Zhu GQ, Zou ZL, Zheng JN, Chen DZ, Zou TT, Shi KQ, Zheng MH. Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1. Medicine (Baltimore) 2016;95:e3004. [PMID: 26945424 DOI: 10.1097/MD.0000000000003004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
87 Tzarum N, Giang E, Kong L, He L, Prentoe J, Augestad E, Hua Y, Castillo S, Lauer GM, Bukh J, Zhu J, Wilson IA, Law M. Genetic and structural insights into broad neutralization of hepatitis C virus by human VH1-69 antibodies. Sci Adv 2019;5:eaav1882. [PMID: 30613781 DOI: 10.1126/sciadv.aav1882] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 16.0] [Reference Citation Analysis]
88 Jancoriene L, Polubenko K, Kazenaite E, Buivydiene A, Jakutiene J, Tolmane I, Jeruma A, Radzisauskiene D, Mockiene E, Ambrozaitis A. Direct-Acting Antivirals Ombitasvir / Paritaprevir / Ritonavir + Dasabuvir with or Without Ribavirin in Hepatitis C Virus (HCV) Genotype 1-Infected Treatment-Naive or Treatment-Experienced Patients with or Without Cirrhosis: Real-Life Experience in Lithuania and Latvia. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.62105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
89 Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, Danziger-isakov L, Kirklin JK, Kirk R, Kushwaha SS, Lund LH, Potena L, Ross HJ, Taylor DO, Verschuuren EA, Zuckermann A. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. The Journal of Heart and Lung Transplantation 2016;35:1-23. [DOI: 10.1016/j.healun.2015.10.023] [Cited by in Crossref: 635] [Cited by in F6Publishing: 482] [Article Influence: 105.8] [Reference Citation Analysis]
90 Majam M, Fischer A, Ivanova Reipold E, Rhagnath N, Msolomba V, Lalla-Edward ST. A Lay-User Assessment of Hepatitis C Virus Self-Testing Device Usability and Interpretation in Johannesburg, South Africa. Diagnostics (Basel) 2021;11:463. [PMID: 33800060 DOI: 10.3390/diagnostics11030463] [Reference Citation Analysis]
91 Chi X, Zhao X, Wang W, Niu Y, Cheng M, Liu X, Cui S, Yang W. Fusion expression of Occludin extracellular loops and an α-helical bundle: A new research model for tight junction. PLoS One 2017;12:e0175516. [PMID: 28448574 DOI: 10.1371/journal.pone.0175516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
92 Hathorn E, Elsharkawy AM. Management of hepatitis C genotype 4 in the directly acting antivirals era. BMJ Open Gastroenterol 2016;3:e000112. [PMID: 27752338 DOI: 10.1136/bmjgast-2016-000112] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
93 Nawaz A, Zaidi SF, Usmanghani K, Ahmad I. Concise review on the insight of hepatitis C. Journal of Taibah University Medical Sciences 2015;10:132-9. [DOI: 10.1016/j.jtumed.2014.08.004] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
94 Nakajima S, Watashi K, Fukano K, Tsukuda S, Wakae K, Aizaki H, Muramatsu M, Wakita T, Toyoda T. Non-nucleoside hepatitis B virus polymerase inhibitors identified by an in vitro polymerase elongation assay. J Gastroenterol 2020;55:441-52. [PMID: 31768802 DOI: 10.1007/s00535-019-01643-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
95 Marnata C, Saulnier A, Mompelat D, Krey T, Cohen L, Boukadida C, Warter L, Fresquet J, Vasiliauskaite I, Escriou N, Cosset FL, Rey FA, Lanford RE, Karayiannis P, Rose NJ, Lavillette D, Martin A. Determinants Involved in Hepatitis C Virus and GB Virus B Primate Host Restriction. J Virol 2015;89:12131-44. [PMID: 26401036 DOI: 10.1128/JVI.01161-15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
96 Chung CY, Liu CH, Burnouf T, Wang GH, Chang SP, Jassey A, Tai CJ, Tai CJ, Huang CJ, Richardson CD, Yen MH, Lin CC, Lin LT. Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry. Antiviral Res 2016;130:58-68. [PMID: 27012176 DOI: 10.1016/j.antiviral.2016.03.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
97 Skaar JR, Pagan JK, Pagano M. SCF ubiquitin ligase-targeted therapies. Nat Rev Drug Discov 2014;13:889-903. [PMID: 25394868 DOI: 10.1038/nrd4432] [Cited by in Crossref: 194] [Cited by in F6Publishing: 186] [Article Influence: 24.3] [Reference Citation Analysis]
98 Tsukuda S, Watashi K, Hojima T, Isogawa M, Iwamoto M, Omagari K, Suzuki R, Aizaki H, Kojima S, Sugiyama M, Saito A, Tanaka Y, Mizokami M, Sureau C, Wakita T. A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins. Hepatology. 2017;65:1104-1116. [PMID: 27863453 DOI: 10.1002/hep.28952] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
99 Politi MC, George N, Li T, Korenblat KM, Fowler KJ, Ho C, Liapakis A, Roth D, Yee J. Project HELP: a study protocol to pilot test a shared decision-making tool about treatment options for patients with hepatitis C and chronic kidney disease. Pilot Feasibility Stud 2018;4:55. [PMID: 29484199 DOI: 10.1186/s40814-018-0251-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
100 Allegra S, Cusato J, De Nicolò A, Boglione L, Gatto A, Cariti G, Di Perri G, D'Avolio A. Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients. Biomed Pharmacother 2015;69:47-55. [PMID: 25661337 DOI: 10.1016/j.biopha.2014.10.030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
101 O'Shea D, Law J, Egli A, Douglas D, Lund G, Forester S, Lambert J, Law M, Burton DR, Tyrrell DL, Houghton M, Humar A, Kneteman N. Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate. Liver Transpl 2016;22:324-32. [PMID: 26389583 DOI: 10.1002/lt.24344] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
102 Helal TEA, Radwan NA, Mahmoud HA, Zaki AM, Ahmed NS, Wahib AA, Aref AM. The role of hepatic progenitor cells in predicting response to therapy in Egyptian patients with chronic hepatitis C, genotype 4. Afr Health Sci 2019;19:1411-21. [PMID: 31148968 DOI: 10.4314/ahs.v19i1.14] [Reference Citation Analysis]
103 Bryan-marrugo O, Ramos-jiménez J, Barrera-saldaña H, Rojas-martínez A, Vidaltamayo R, Rivas-estilla A. History and progress of antiviral drugs: From acyclovir to direct-acting antiviral agents (DAAs) for Hepatitis C. Medicina Universitaria 2015;17:165-74. [DOI: 10.1016/j.rmu.2015.05.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
104 Khairy RMM, Hmmad SS, Sayed M, Ahmed HA, Esmail MAM. Serum MicroRNAs as predictors for fibrosis progression and response to direct-acting antivirals treatment in hepatitis C virus genotype-4 Egyptian patients. Int J Clin Pract 2021;75:e13954. [PMID: 33345414 DOI: 10.1111/ijcp.13954] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
105 Stahmeyer JT, Rossol S, Bert F, Böker KH, Bruch HR, Eisenbach C, Link R, John C, Mauss S, Heyne R, Schott E, Pfeiffer-Vornkahl H, Hüppe D, Krauth C. Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study. PLoS One 2016;11:e0159976. [PMID: 27467772 DOI: 10.1371/journal.pone.0159976] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
106 Rozada I, Coombs D, Lima VD. Conditions for eradicating hepatitis C in people who inject drugs: A fibrosis aware model of hepatitis C virus transmission. J Theor Biol 2016;395:31-9. [PMID: 26845310 DOI: 10.1016/j.jtbi.2016.01.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
107 Ethgen O, Sanchez Gonzalez Y, Jeanblanc G, Duguet A, Misurski D, Juday T. Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population. Journal of Medical Economics 2017;20:162-70. [DOI: 10.1080/13696998.2016.1232725] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
108 Coppola N, Pisaturo M, Sagnelli C, Onorato L, Sagnelli E. Role of genetic polymorphisms in hepatitis C virus chronic infection. World J Clin Cases 2015; 3(9): 807-822 [PMID: 26380828 DOI: 10.12998/wjcc.v3.i9.807] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
109 Hung TC, Jassey A, Lin CJ, Liu CH, Lin CC, Yen MH, Lin LT. Methanolic Extract of Rhizoma Coptidis Inhibits the Early Viral Entry Steps of Hepatitis C Virus Infection. Viruses 2018;10:E669. [PMID: 30486350 DOI: 10.3390/v10120669] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
110 Yu Y, Wan Z, Wang JH, Yang X, Zhang C. Review of human pegivirus: Prevalence, transmission, pathogenesis, and clinical implication. Virulence 2022;13:324-41. [PMID: 35132924 DOI: 10.1080/21505594.2022.2029328] [Reference Citation Analysis]
111 Nehme Z, Pasquereau S, Herbein G. Control of viral infections by epigenetic-targeted therapy. Clin Epigenetics 2019;11:55. [PMID: 30917875 DOI: 10.1186/s13148-019-0654-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 12.7] [Reference Citation Analysis]
112 Rizk HH, Hamdy NM, Al-Ansari NL, El-Mesallamy HO. Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4. PLoS One 2016;11:e0153895. [PMID: 27100663 DOI: 10.1371/journal.pone.0153895] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
113 Martı́nez-gonzález JÁ, González M, Masgrau L, Martı́nez R. Theoretical Study of the Free Energy Surface and Kinetics of the Hepatitis C Virus NS3/NS4A Serine Protease Reaction with the NS5A/5B Substrate. Does the Generally Accepted Tetrahedral Intermediate Really Exist? ACS Catal 2015;5:246-55. [DOI: 10.1021/cs5011162] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
114 You Y, Kim HS, Bae IH, Lee SG, Jee MH, Keum G, Jang SK, Kim BM. New potent biaryl sulfate-based hepatitis C virus inhibitors. Eur J Med Chem 2017;125:87-100. [PMID: 27657807 DOI: 10.1016/j.ejmech.2016.09.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
115 Chen R, Kobewka M, Addison W, Lachance G, Tyrrell DL. Intrinsic Viral Factors Are the Dominant Determinants of the Hepatitis C Virus Response to Interferon Alpha Treatment in Chimeric Mice. PLoS One 2016;11:e0147007. [PMID: 26765841 DOI: 10.1371/journal.pone.0147007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
116 Uddin R, Downard KM. Molecular basis of benzimidazole inhibitors to hepatitis C virus envelope glycoprotein. Chem Biol Drug Des 2018;92:1638-46. [DOI: 10.1111/cbdd.13329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
117 Hartling HJ, Birch C, Gaardbo JC, Hove M, Trøseid M, Clausen MR, Gerstoft J, Ullum H, Nielsen SD. T-cell homeostasis in chronic HCV-infected patients treated with interferon and ribavirin or an interferon-free regimen. APMIS 2015;123:903-11. [PMID: 26279289 DOI: 10.1111/apm.12429] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
118 Chou ML, Burnouf T, Chang SP, Hung TC, Lin CC, Richardson CD, Lin LT. TnBP⁄Triton X-45 treatment of plasma for transfusion efficiently inactivates hepatitis C virus. PLoS One 2015;10:e0117800. [PMID: 25658612 DOI: 10.1371/journal.pone.0117800] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
119 Abergel A, Rotily M, Branchoux S, Akremi R, de Léotoing L, Vainchtock A, Gaudin A. Chronic hepatitis C: Burden of disease and cost associated with hospitalisations in France in 2012 (The HEPC-LONE study). Clinics and Research in Hepatology and Gastroenterology 2016;40:340-8. [DOI: 10.1016/j.clinre.2015.08.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
120 Gallay P, Ure D, Bobardt M, Chatterji U, Ou J, Trepanier D, Foster R. The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice. PLoS One. 2019;14:e0217433. [PMID: 31181107 DOI: 10.1371/journal.pone.0217433] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
121 Walker DR, Pedrosa MC, Manthena SR, Patel N, Marx SE. Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV). Adv Ther 2015;32:1117-27. [PMID: 26538232 DOI: 10.1007/s12325-015-0258-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
122 Maan R, van der Meer AJ. Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. F1000Res 2016;5:F1000 Faculty Rev-367. [PMID: 27006761 DOI: 10.12688/f1000research.7399.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
123 Siqueira FM, Ferreira VL, Borba HHL, Pontarolo R. Quality of life of Brazilian chronic hepatitis C patients treated with interferon-free therapies. Rev Inst Med Trop Sao Paulo. 2018;60:e72. [PMID: 30462795 DOI: 10.1590/s1678-9946201860072] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
124 de Ruiter PE, Boor PP, de Jonge J, Metselaar HJ, Tilanus HW, Ijzermans JN, Kwekkeboom J, van der Laan LJ. Prednisolone does not affect direct-acting antivirals against hepatitis C, but inhibits interferon-alpha production by plasmacytoid dendritic cells. Transpl Infect Dis. 2015;17:707-715. [PMID: 26250892 DOI: 10.1111/tid.12430] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
125 McPhee F, Ueland J, Vellucci V, Bowden S, Sievert W, Zhou N. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the In Vitro Potency of Direct-Acting Antiviral Agents. Antimicrob Agents Chemother 2019;63:e02205-18. [PMID: 30718256 DOI: 10.1128/AAC.02205-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
126 Kong L, Jackson KN, Wilson IA, Law M. Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design. Curr Opin Virol 2015;11:148-57. [PMID: 25932568 DOI: 10.1016/j.coviro.2015.04.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
127 Schwarz KB, Molleston JP, Jonas MM, Wen J, Murray KF, Rosenthal P, Gonzalez-peralta RP, Lobritto SJ, Mogul D, Pavlovic V, Warne C, Wat C, Thompson B. Durability of Response in Children Treated With Pegylated Interferon alfa-2a ± Ribavirin for Chronic Hepatitis C. Journal of Pediatric Gastroenterology & Nutrition 2016;62:93-6. [DOI: 10.1097/mpg.0000000000000929] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
128 Attar BM, Van Thiel D. A New Twist to a Chronic HCV Infection: Occult Hepatitis C. Gastroenterol Res Pract. 2015;2015:579147. [PMID: 26221136 DOI: 10.1155/2015/579147] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
129 Khairy RM, Abdulghany HM, Abdel-Raheim S, Zenhom NM, Abd Elfatah AS, Abdalla NH. Association of IL-1β, IL-1RN, and ESR1 genes polymorphism with risk of infection and response to sofosbuvir plus daclatasvir combination therapy in hepatitis C virus genotype-4 patients. IUBMB Life 2018;70:1156-63. [PMID: 30253037 DOI: 10.1002/iub.1929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
130 Liu CH, Lin CC, Hsu WC, Chung CY, Lin CC, Jassey A, Chang SP, Tai CJ, Tai CJ, Shields J, Richardson CD, Yen MH, Tyrrell DLJ, Lin LT. Highly bioavailable silibinin nanoparticles inhibit HCV infection. Gut 2017;66:1853-61. [PMID: 27436270 DOI: 10.1136/gutjnl-2016-312019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
131 Sise ME, Wisocky J, Rosales IA, Chute D, Holmes JA, Corapi KM, Babitt JL, Tangren JS, Hashemi N, Lundquist AL, Williams WW, Mount DB, Andersson KL, Rennke HG, Smith RN, Colvin R, Thadhani RI, Chung RT. Lupus-like Immune Complex-mediated Glomerulonephritis in Patients with Hepatitis C Virus Infection Treated with Oral, Interferon-free, Direct-acting Antiviral Therapy. Kidney Int Rep 2016;1:135-43. [PMID: 27990496 DOI: 10.1016/j.ekir.2016.06.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
132 Morozov VA, Lagaye S. Hepatitis C virus: Morphogenesis, infection and therapy. World J Hepatol 2018; 10(2): 186-212 [PMID: 29527256 DOI: 10.4254/wjh.v10.i2.186] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
133 Chatterji U, Bobardt M, Tai A, Wood M, Gallay PA. Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories. Antimicrob Agents Chemother. 2015;59:2496-2507. [PMID: 25666154 DOI: 10.1128/aac.04958-14] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
134 Triyatni M, Berger EA, Saunier B. Assembly and release of infectious hepatitis C virus involving unusual organization of the secretory pathway. World J Hepatol 2016; 8(19): 796-814 [PMID: 27429716 DOI: 10.4254/wjh.v8.i19.796] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
135 Suwanthawornkul T, Anothaisintawee T, Sobhonslidsuk A, Thakkinstian A, Teerawattananon Y. Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis. PLoS One 2015;10:e0145953. [PMID: 26720298 DOI: 10.1371/journal.pone.0145953] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 6.1] [Reference Citation Analysis]
136 Gogela NA, Lin MV, Wisocky JL, Chung RT. Enhancing our understanding of current therapies for hepatitis C virus (HCV). Curr HIV/AIDS Rep 2015;12:68-78. [PMID: 25761432 DOI: 10.1007/s11904-014-0243-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
137 Hsu W, Chang S, Lin L, Li C, Richardson CD, Lin C, Lin L. Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry. Antiviral Research 2015;118:139-47. [DOI: 10.1016/j.antiviral.2015.04.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
138 van Cleef KW, Overheul GJ, Thomassen MC, Marjakangas JM, van Rij RP. Escape Mutations in NS4B Render Dengue Virus Insensitive to the Antiviral Activity of the Paracetamol Metabolite AM404. Antimicrob Agents Chemother 2016;60:2554-7. [PMID: 26856827 DOI: 10.1128/AAC.02462-15] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
139 Zhou N, Han Z, Hartman-Neumann S, DeGray B, Ueland J, Vellucci V, Hernandez D, McPhee F. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens. J Antimicrob Chemother 2016;71:3495-505. [PMID: 27605597 DOI: 10.1093/jac/dkw336] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
140 Frustaci A, Petrosillo N, Vizza D, Francone M, Badagliacca R, Verardo R, Fedele F, Ippolito G, Chimenti C. Myocardial and microvascular inflammation/infection in patients with HIV-associated pulmonary artery hypertension. AIDS 2014;28:2541-9. [PMID: 25144217 DOI: 10.1097/QAD.0000000000000426] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]